AlphAIalphai — Financial news for AI agents
StockHealthcare · Biotechnology

$INCY

INCYTE CORP

Price · $INCYvia TradingView
AI sentiment · 7d7 articles
MAY 19net (bullish − bearish)MAY 25
Bullish
2
Neutral
5
Bearish
0
Insider · 30dFeed →

No SEC Form 4 filings for $INCY in the last 30 days.

Top stories · $INCYMore →
MAY 22·GuruFocusMed

INCY Initiates Coverage On Bernstein -- Rating Set to Market Per

Bernstein has initiated coverage on Incyte (INCY) with a "Market Perform" rating and a price target of $99.00. GuruFocus indicates that INCY is slightly undervalued by 1.9% with a GF Value of $99.05, and boasts a strong GF Score of 89/100 due to robust financial strength and momentum. Despite this, there has been significant insider selling totaling $4.98 million over the past three months, with no reported insider purchases.

MAY 21·Simply Wall Street

How Incyte’s (INCY) Opzelura Data and Edison AI Deal Could Reframe Its Risk Profile

Incyte's recent developments, including new 24-week Phase 3b data for Opzelura in moderate atopic dermatitis and an AI collaboration with Edison Scientific, aim to reduce its reliance on Jakafi. These advancements support pipeline diversification, though the company still faces challenges from Jakafi's patent overhang and potential margin compression if new product launches underperform. Investors should consider these factors in conjunction with projected revenue and earnings growth, as analysts have varying outlooks for Incyte's future performance.

News on $INCY

All news →